<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENTS OF ARONEX PHARMACEUTICALS, INC. SET FORTH IN THE COMPANY'S FORM 10-K FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1 <PERIOD-TYPE> 12-MOS <FISCAL-YEAR-END> DEC-31-1996 <PERIOD-END> DEC-31-1996 <CASH> 4,179,000 <SECURITIES> 37,209,000 <RECEIVABLES> 78,000 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 35,334,000 <PP&E> 5,021,000 <DEPRECIATION> 2,869,000 <TOTAL-ASSETS> 44,281,000 <CURRENT-LIABILITIES> 3,658,000 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 15,000 <OTHER-SE> 40,462,000 <TOTAL-LIABILITY-AND-EQUITY> 44,281,000 <SALES> 0 <TOTAL-REVENUES> 4,362,000 <CGS> 0 <TOTAL-COSTS> 0 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 173,000 <INCOME-PRETAX> (8,030,000) <INCOME-TAX> 0 <INCOME-CONTINUING> (8,030,000) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (8,030,000) <EPS-PRIMARY> (0.62) <EPS-DILUTED> (0.62)